Trends in Prevalence and Disability-Adjusted Life-Years of Alzheimer’s Disease and Other Dementias in China from 1990 to 2019

Abstract

<b><i>Introduction:</i></b> China has the largest population of people with dementia in the world and is estimated to have approximately a quarter of the entire population with dementia worldwide, bringing a heavy burden on the public and healthcare systems. We aimed to analyze the burden of Alzheimer’s disease and other dementias in China over the past three decades. <b><i>Methods:</i></b> The data on disease burden owing to Alzheimer’s disease and other dementias in China from 1990 to 2019 were extracted from the Global Burden of Disease (GBD) 2019 datasets. The estimated annual percentage changes (EAPCs) were calculated to assess the temporal trends, and the ratio of years lived with disability (YLDs) to disability-adjusted life-years (DALYs) was used as an indicator to evaluate the healthcare system. <b><i>Result:</i></b> In China, the overall age-standardized rates (ASRs) of the prevalence and DALYs of Alzheimer’s disease and other dementias increased from 1990 to 2019, and their EAPCs were 0.66 (95% confidence interval [CI], 0.57–0.75) and 0.26 (95% CI, 0.21–0.31), respectively. ASRs and the total number of dementia in females remained higher than in males, but the upward trend in ASRs among men was more pronounced than in women. The female-to-male ratio of the age-standardized DALY rate peaked in the 75–79 year age group in 2019 (female-to-male ratio of 1.32). The YLDs:DALYs ratio in China experienced a gradual increase and finally stayed above the global average since 2011. <b><i>Conclusion:</i></b> China has experienced a remarkably rising burden of dementia over the past three decades. The more significant burden of dementia was in females, but the potentially increasing burden of dementia in males cannot be underestimated.

Bioaccumulation of Microplastics in Decedent Human Brains Assessed by Pyrolysis Gas Chromatography-Mass Spectrometry

“…However, linking MNP concentration data to health outcomes in larger cohorts will require re nements to the technique, more complex study designs, and larger cohorts. The parallels between the present data showing an increasing trend in MNP concentrations in the brain with exponentially rising environmental presence of microplastics [19][20][21] and increasing global rates of age-corrected Alzheimer's disease and related dementia [22][23][24][25] , given the potential role of anionic nanoplastics in protein aggregation 26 , add urgency to understanding the impacts of MNP on human health. Example TEM images of solid nanoparticulates derived from kidney (left), liver (center), and brain (right) samples.…”

Changing profiles of the burden of Alzheimer's disease and other dementias attributable to smoking in the belt and road initiative countries: A secondary analysis of global burden of disease 2019

“…The adoption of China's tobacco control policy, 2015, appears to have reduced the number of hospitalizations for all cardiovascular diseases by more than 10%, while increasing the number of hospitalizations due to cerebrovascular diseases by over 20% [ 14 ]. China National Tobacco Corporation, the world's largest cigarette manufacturer, has also released a "Tobacco Industry in Belt and Road Development Plan" [ 8 , 15 ].…”

Depressive symptom mediates the association between the number of chronic diseases and cognitive impairment: a multi-center cross-sectional study based on community older adults

“…The fight against Alzheimer’s disease (AD) is considered a public health priority by the World Health Organization (WHO) ( 1 ). As of 2019, there are at least 50 million AD patients worldwide, and it is expected to reach 152 million by 2050, while China will reach 28.98 million ( 2 ). Mild cognitive impairment (MCI) is a cognitive stage between normal cognition and dementia, and is the primary sign of cognitive change.…”